Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

NASH Drug Development Guidance Encourages Sponsors To Adopt Innovative Trial Designs

Dec 05 2018

• By Michael Cipriano

Liver

Related Content

Woodcock Hopes I-SPY 2 Trial Is 'Blazing The Trail' For Future Adaptive Design Uptake

Sep 13 2018

Galectin Hopes To Set Surrogate Endpoints For NASH Cirrhosis, Despite Trial Failure

Sep 28 2016

“One Continuous Trial” In Oncology: US FDA Offers Guidance And Encouragement

Aug 22 2018

'Clean Label' For Intercept's Ocaliva In PBC Bodes Well For NASH Claim

Jun 06 2016

Galectin Offers Subgroup Approach For Struggling NASH Candidate

Dec 06 2017

New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib

Apr 20 2018

Pfizer Working To Catch Up In NASH With Fat-Reducing Compounds

Apr 30 2018

Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC

Nov 10 2018

Related Companies

Intercept Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Allergan plc

Genfit SA

Galectin Therapeutics Inc.

Additional Topics

United States Clinical Trials Research & Development Regulation Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window